Evaluating the effect of sildenafil on the prevention of Anthracyclines induced acute cardiotoxicity

Evaluating the effect of sildenafil on the prevention of Anthracycline induced acute cardiotoxicity in cancerous patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180506039554N1

Enrollment

Registered

2018-05-29

Start date

2017-08-15

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention 1: Intervention group:Usage od sildenafil tablet 25 mg two times daily. Intervention 2: Control group: Failure to do extra work.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having Breast cancer or Non.hojkin lymphoma Don,t usage of radiotherapy as a part of cancer treatment

Exclusion criteria

Exclusion criteria: History of CAD History of CHF History of severe valvular heart disease Usage of nitrate for any causes Having severe chronic disease such as renal failure,liver failure and autoimmune diseases Concomitant usage of Betablocker,ACE,Statins Systolic BP < 100

Design outcomes

Primary

Measure	Time frame
LV Ejection fraction and diastolic function of the heart. Timepoint: Before and after 6 dose of chemotherapy with anthracyclin. Method of measurement: Calculate Lv Ejection fraction with 3D Echocardiography and diatolic function with speckled tracking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Heydari

Shiraz University of Medical Sciences

heydari_m@sums.ac.ir+98 71 3233 2336

Outcome results